Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Original Article

M.A. Dimopoulos, P.M. Voorhees, F. Schjesvold, Y.C. Cohen, V. Hungria, I. Sandhu, J. Lindsay, R.I. Baker, K. Suzuki, H. Kosugi, M.-D. Levin, M. Beksac, K. Stockerl-Goldstein, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, A.K. Mylin, S. Bringhen, K. Uttervall, B. Pula, E. Medvedova, A.J. Cowan, P. Moreau, M.-V. Mateos, H. Goldschmidt, T. Ahmadi, L. Sha, A. Cortoos, E.G. Katz, E. Rousseau, L. Li, R.M. Dennis, R. Carson, and S.V. Rajkumar

N Engl J Med 2025;392:1777-1788

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
05/07/2025
Course expires: 
05/08/2027

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.